BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chou CC, Shen CF, Chen SJ, Chen HM, Wang YC, Chang WS, Chang YT, Chen WY, Huang CY, Kuo CC, Li MC, Lin JF, Lin SP, Ting SW, Weng TC, Wu PS, Wu UI, Lin PC, Lee SS, Chen YS, Liu YC, Chuang YC, Yu CJ, Huang LM, Lin MC; Infectious Diseases Society of Taiwan;., Taiwan Society of Pulmonary and Critical Care Medicine,., Medical Foundation in Memory of Dr. Deh-Lin Cheng;., Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education;., CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines,., 4th Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group. Recommendations and guidelines for the treatment of pneumonia in Taiwan. J Microbiol Immunol Infect 2019;52:172-99. [PMID: 30612923 DOI: 10.1016/j.jmii.2018.11.004] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924. [PMID: 32081636 DOI: 10.1016/j.ijantimicag.2020.105924] [Reference Citation Analysis]
2 Jean SS, Chang YC, Lin WC, Lee WS, Hsueh PR, Hsu CW. Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia. J Clin Med 2020;9:E275. [PMID: 31963877 DOI: 10.3390/jcm9010275] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
3 Chen FL, Wang CH, Hung CS, Su YS, Lee WS. Co-infection with an atypical pathogen of COVID-19 in a young. J Microbiol Immunol Infect 2021;54:154-5. [PMID: 32505530 DOI: 10.1016/j.jmii.2020.05.007] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Triana AJ, Molinares JL, Del Rio‐pertuz G, Meza JL, Ariza‐bolívar O, Robledo‐solano A, Acosta‐reyes J. Clinical practice guidelines for the management of community‐acquired pneumonia: A critical appraisal using the AGREE II instrument. Int J Clin Pract 2020;74. [DOI: 10.1111/ijcp.13478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Yiang GT, Tzeng IS, Shui HA, Wu MY, Peng MY, Chan CY, Chan ED, Wu YK, Lan CC, Yang MC, Huang KL, Wu CW, Chang CH, Su WL. Early Screening of Risk for Multidrug-Resistant Organisms in the Emergency Department in Patients With Pneumonia and Early Septic Shock: Single-Center, Retrospective Cohort Study. Shock 2021;55:198-209. [PMID: 32694392 DOI: 10.1097/SHK.0000000000001599] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Lai C, Shih T, Ko W, Tang H, Hsueh P. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International Journal of Antimicrobial Agents 2020;55:105924. [DOI: 10.1016/j.ijantimicag.2020.105924] [Reference Citation Analysis]
7 Hackert VH, Dukers-Muijrers NHTM, Hoebe CJPA. Signs and symptoms do not predict, but may help rule out acute Q fever in favour of other respiratory tract infections, and reduce antibiotics overuse in primary care. BMC Infect Dis 2020;20:690. [PMID: 32957938 DOI: 10.1186/s12879-020-05400-0] [Reference Citation Analysis]
8 Huang WH, Teng LC, Yeh TK, Chen YJ, Lo WJ, Wu MJ, Chin CS, Tsan YT, Lin TC, Chai JW, Lin CF, Tseng CH, Liu CW, Wu CM, Chen PY, Shi ZY, Liu PY. 2019 novel coronavirus disease (COVID-19) in Taiwan: Reports of two cases from Wuhan, China. J Microbiol Immunol Infect. 2020;53:481-484. [PMID: 32111449 DOI: 10.1016/j.jmii.2020.02.009] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 20.5] [Reference Citation Analysis]
9 Martí M, Tuñón-Molina A, Aachmann FL, Muramoto Y, Noda T, Takayama K, Serrano-Aroca Á. Protective Face Mask Filter Capable of Inactivating SARS-CoV-2, and Methicillin-Resistant Staphylococcus aureus and Staphylococcus epidermidis. Polymers (Basel) 2021;13:E207. [PMID: 33435608 DOI: 10.3390/polym13020207] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
10 Kuo SC, Liu CE, Lu PL, Chen YS, Lu MC, Ko WC, Hsueh PR, Chuang YC, Wang FD; SMART Asia-Pacific Group. Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016. Int J Antimicrob Agents 2020;55:105883. [PMID: 31923574 DOI: 10.1016/j.ijantimicag.2020.105883] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
11 Lee SH, Ruan SY, Pan SC, Lee TF, Chien JY, Hsueh PR. Performance of a multiplex PCR pneumonia panel for the identification of respiratory pathogens and the main determinants of resistance from the lower respiratory tract specimens of adult patients in intensive care units. J Microbiol Immunol Infect 2019;52:920-8. [PMID: 31806539 DOI: 10.1016/j.jmii.2019.10.009] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 13.7] [Reference Citation Analysis]
12 Chen CH, Tu CY, Chen WC, Kuo LK, Wang YT, Fu PK, Ku SC, Fang WF, Chen CM, Lai CC. Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. Infect Drug Resist 2021;14:2251-8. [PMID: 34168466 DOI: 10.2147/IDR.S313828] [Reference Citation Analysis]
13 Hoseinzadeh E, Safoura Javan, Farzadkia M, Mohammadi F, Hossini H, Taghavi M. An updated min-review on environmental route of the SARS-CoV-2 transmission. Ecotoxicol Environ Saf 2020;202:111015. [PMID: 32800237 DOI: 10.1016/j.ecoenv.2020.111015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
14 Li H, Wang H, Wang Y, Wang J, Huo X, Zhao Q. Management of Ventilator-Associated Pneumonia: Quality Assessment of Clinical Practice Guidelines and Variations in Recommendations on Drug Therapy for Prevention and Treatment. Front Pharmacol 2022;13:903378. [DOI: 10.3389/fphar.2022.903378] [Reference Citation Analysis]
15 Jean SS, Lee WS, Ko WC, Hsueh PR. In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018. J Microbiol Immunol Infect 2021;54:627-31. [PMID: 32451293 DOI: 10.1016/j.jmii.2020.04.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Mazloomirad F, Hasanzadeh S, Sharifi A, Nikbakht G, Roustaei N, Khoramrooz SS. Identification and detection of pathogenic bacteria from patients with hospital-acquired pneumonia in southwestern Iran; evaluation of biofilm production and molecular typing of bacterial isolates. BMC Pulm Med 2021;21:408. [PMID: 34886838 DOI: 10.1186/s12890-021-01773-3] [Reference Citation Analysis]
17 Huang C. The COVID-19 Pandemic and the Incidence of the Non-COVID-19 Pneumonia in Adults. Front Med (Lausanne) 2021;8:737999. [PMID: 34859006 DOI: 10.3389/fmed.2021.737999] [Reference Citation Analysis]
18 Chiu CC, Wang CJ, Lee WI, Wong KS, Chiu CY, Lai SH. Pulmonary function evaluation in pediatric patients with primary immunodeficiency complicated by bronchiectasis. J Microbiol Immunol Infect 2020;53:1014-20. [PMID: 32094076 DOI: 10.1016/j.jmii.2020.01.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Zheng JY, Huang SS, Huang SH, Ye JJ. Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Microbiol Immunol Infect 2020;53:854-65. [PMID: 31607573 DOI: 10.1016/j.jmii.2019.08.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Su WL, Shui HA, Peng MY. Ignorance of pre-ED healthcare setting is a factor leading to inappropriate initial antibiotic treatment of sepsis in ED and poor outcomes in ICU. J Microbiol Immunol Infect 2020;53:532-41. [PMID: 31917133 DOI: 10.1016/j.jmii.2019.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Arjunan A, Robinson J, Baroutaji A, Tuñón-Molina A, Martí M, Serrano-Aroca Á. 3D Printed Cobalt-Chromium-Molybdenum Porous Superalloy with Superior Antiviral Activity. Int J Mol Sci 2021;22:12721. [PMID: 34884526 DOI: 10.3390/ijms222312721] [Reference Citation Analysis]
22 Lan S, Lai C, Chang S, Lu L, Hung S, Lin W. Five-day antibiotic treatment for community-acquired bacterial pneumonia: A systematic review and meta-analysis of randomized controlled trials. Journal of Global Antimicrobial Resistance 2020;23:94-9. [DOI: 10.1016/j.jgar.2020.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Dong YH, Chang CH, Wang JL, Wu LC, Lin JW, Toh S. Association of Infections and Use of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection. JAMA Intern Med 2020;180:1587-95. [PMID: 32897358 DOI: 10.1001/jamainternmed.2020.4192] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
24 Lai CC, Lu CT, Kao KC, Lu MC, Ko WC, Hsueh PR. Association of fluoroquinolones use with the risk of aortic aneurysm or aortic dissection: Facts and myths. J Microbiol Immunol Infect 2021;54:182-4. [PMID: 33775552 DOI: 10.1016/j.jmii.2021.03.002] [Reference Citation Analysis]
25 Lan SH, Chang SP, Lai CC, Lu LC, Chao CM. Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med 2019;8:E824. [PMID: 31181859 DOI: 10.3390/jcm8060824] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
26 Jerry Teng CL, Wang PN, Chen YC, Ko BS. Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review. J Microbiol Immunol Infect 2021;54:341-8. [PMID: 33514495 DOI: 10.1016/j.jmii.2021.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Chen Y, Kao Y, Hsu C, Chen C, Ma Y, Shen Y, Liu T, Hsu S, Lin H, Wang J, Huang C, Liu C. Real‐time interactive artificial intelligence of things–based prediction for adverse outcomes in adult patients with pneumonia in the emergency department. Acad Emerg Med 2021;28:1277-85. [DOI: 10.1111/acem.14339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Kabir MT, Uddin MS, Hossain MF, Abdulhakim JA, Alam MA, Ashraf GM, Bungau SG, Bin-Jumah MN, Abdel-Daim MM, Aleya L. nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics. Front Cell Dev Biol 2020;8:616. [PMID: 32754599 DOI: 10.3389/fcell.2020.00616] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
29 Shntaif AH, Alrazzak NA, Bader A, Almarzoqi AM; University of Babylon, College of Science for Women, Iraq, University of Babylon, College of Science for Women, Iraq, University of Babylon, College of Science for Women, Iraq, University of Babylon, College of Science for Women, Iraq. Determination the binding ability of N-acetyl cysteine and its derivatives with SARS-COV-2 main protease using molecular docking and molecular dynamics studies. Ukr Biochem J 2021;93:43-51. [DOI: 10.15407/ubj93.05.043] [Reference Citation Analysis]
30 Liu YC, Cheng HY, Chang TH, Ho TW, Liu TC, Yen TY, Chou CC, Chang LY, Lai F. Evaluation of the Need for Intensive Care in Children With Pneumonia: Machine Learning Approach. JMIR Med Inform 2022;10:e28934. [PMID: 35084358 DOI: 10.2196/28934] [Reference Citation Analysis]
31 Takayama K, Tuñón-Molina A, Cano-Vicent A, Muramoto Y, Noda T, Aparicio-Collado JL, Sabater I Serra R, Martí M, Serrano-Aroca Á. Non-Woven Infection Prevention Fabrics Coated with Biobased Cranberry Extracts Inactivate Enveloped Viruses Such as SARS-CoV-2 and Multidrug-Resistant Bacteria. Int J Mol Sci 2021;22:12719. [PMID: 34884521 DOI: 10.3390/ijms222312719] [Reference Citation Analysis]
32 Covián C, Ríos M, Berríos-Rojas RV, Bueno SM, Kalergis AM. Induction of Trained Immunity by Recombinant Vaccines. Front Immunol 2020;11:611946. [PMID: 33584692 DOI: 10.3389/fimmu.2020.611946] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Lin Z, Yu J, Liu S, Zhu M. Prevalence and antibiotic resistance of Klebsiella pneumoniae in a tertiary hospital in Hangzhou, China, 2006-2020. J Int Med Res 2022;50:3000605221079761. [PMID: 35216543 DOI: 10.1177/03000605221079761] [Reference Citation Analysis]
34 Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 2020;53:505-512. [PMID: 32482366 DOI: 10.1016/j.jmii.2020.05.013] [Cited by in Crossref: 120] [Cited by in F6Publishing: 109] [Article Influence: 60.0] [Reference Citation Analysis]
35 Feng JY, Peng CK, Sheu CC, Lin YC, Chan MC, Wang SH, Chen CM, Shen YC, Zheng ZR, Lin YT, Yang KY; T-CARE (Taiwan Critical Care and Infection) Group. Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant Gram-negative bacterial pneumonia: a multi-centre observational study. Clin Microbiol Infect 2021:S1198-743X(21)00047-1. [PMID: 33540113 DOI: 10.1016/j.cmi.2021.01.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Shakeel S, Iffat W, Qamar A, Ghuman F, Yamin R, Ahmad N, Ishaq SM, Gajdács M, Patel I, Jamshed S. Pediatricians' Compliance to the Clinical Management Guidelines for Community-Acquired Pneumonia in Infants and Young Children in Pakistan. Healthcare (Basel) 2021;9:701. [PMID: 34207813 DOI: 10.3390/healthcare9060701] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924. [PMID: 32081636 DOI: 10.1016/j.ijantimicag.2020.105924] [Cited by in Crossref: 2043] [Cited by in F6Publishing: 1654] [Article Influence: 1021.5] [Reference Citation Analysis]
38 Chan WP, Yao MS, Lin MF, Chang HC, Kosik RO, Lee WS. Management and infection control practices in a Taiwanese radiology department during the COVID-19 outbreak. J Microbiol Immunol Infect 2021;54:349-58. [PMID: 33863652 DOI: 10.1016/j.jmii.2021.03.012] [Reference Citation Analysis]
39 Huang CC, Chen TH, Ho CH, Chen YC, Hsu CC, Lin HJ, Wang JJ, Chang CP, Guo HR. Increased Risk of Congestive Heart Failure Following Carbon Monoxide Poisoning. Circ Heart Fail 2021;14:e007267. [PMID: 33866825 DOI: 10.1161/CIRCHEARTFAILURE.120.007267] [Reference Citation Analysis]
40 Tuñón-Molina A, Martí M, Muramoto Y, Noda T, Takayama K, Serrano-Aroca Á. Antimicrobial Face Shield: Next Generation of Facial Protective Equipment against SARS-CoV-2 and Multidrug-Resistant Bacteria. Int J Mol Sci 2021;22:9518. [PMID: 34502431 DOI: 10.3390/ijms22179518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Montes-Andujar L, Tinoco E, Baez-Pravia O, Martin-Saborido C, Blanco-Schweizer P, Segura C, Prol Silva E, Reyes V, Rodriguez Cobo A, Zurdo C, Angel V, Varona O, Valero J, Suarez Del Villar R, Ortiz G, Villanueva J, Menéndez J, Blanco J, Torres A, Cardinal-Fernández PA. Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis. Thorax 2021:thoraxjnl-2019-214054. [PMID: 33723019 DOI: 10.1136/thoraxjnl-2019-214054] [Reference Citation Analysis]
42 Lee CH, Lin HW, Lee NY, Lin SH, Li YH. Risk of infectious events in acute myocardial infarction patients treated with ticagrelor or clopidogrel. Eur J Intern Med 2021;85:121-3. [PMID: 33199177 DOI: 10.1016/j.ejim.2020.10.016] [Reference Citation Analysis]
43 Chen YC, Hsu WY, Chang TH. Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia. Emerg Infect Dis 2020;26:1382-91. [PMID: 32568052 DOI: 10.3201/eid2607.200017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
44 Jean SS, Ko WC, Hsueh PR; SMART Study Group. Susceptibility of clinical isolates of meticillin-resistant Staphylococcus aureus and phenotypic non-extended-spectrum β-lactamase-producing Klebsiella pneumoniae to ceftaroline in Taiwan: Results from Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018 and Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2018-2019. Int J Antimicrob Agents 2020;56:106016. [PMID: 32422316 DOI: 10.1016/j.ijantimicag.2020.106016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
45 Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020;53:436-443. [PMID: 32307245 DOI: 10.1016/j.jmii.2020.03.034] [Cited by in Crossref: 218] [Cited by in F6Publishing: 180] [Article Influence: 109.0] [Reference Citation Analysis]
46 Chao C, Lai C, Lee C, Tang H. Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease. Antibiotics 2022;11:610. [DOI: 10.3390/antibiotics11050610] [Reference Citation Analysis]
47 Lin HC, Liu YC, Hsing TY, Chen LL, Liu YC, Yen TY, Lu CY, Chang LY, Chen JM, Lee PI, Huang LM, Lai FP. RSV pneumonia with or without bacterial co-infection among healthy children. J Formos Med Assoc 2021:S0929-6646(21)00388-0. [PMID: 34446339 DOI: 10.1016/j.jfma.2021.08.012] [Reference Citation Analysis]
48 Jean SS, Chang LW, Hsueh PR. Tentative clinical breakpoints and epidemiological cut-off values of nemonoxacin for Streptococcus pneumoniae and Staphylococcus aureus isolates associated with community-acquired pneumonia. J Glob Antimicrob Resist 2020;23:388-93. [PMID: 33207229 DOI: 10.1016/j.jgar.2020.10.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
49 Huang CT, Chen CH, Chen WC, Wang YT, Lai CC, Fu PK, Kuo LK, Chen CM, Fang WF, Tu CY, Ku SC. Clinical effectiveness of cefoperazone-sulbactam versus piperacillin-tazobactam for the treatment of pneumonia in the elderly population. Int J Antimicrob Agents 2021;:106491. [PMID: 34871744 DOI: 10.1016/j.ijantimicag.2021.106491] [Reference Citation Analysis]
50 Chee E, Huang K, Haggie S, Britton PN. Systematic review of clinical practice guidelines on the management of community acquired pneumonia in children. Paediatric Respiratory Reviews 2022. [DOI: 10.1016/j.prrv.2022.01.006] [Reference Citation Analysis]
51 Serrano-Aroca Á, Takayama K, Tuñón-Molina A, Seyran M, Hassan SS, Pal Choudhury P, Uversky VN, Lundstrom K, Adadi P, Palù G, Aljabali AAA, Chauhan G, Kandimalla R, Tambuwala MM, Lal A, Abd El-Aziz TM, Sherchan S, Barh D, Redwan EM, Bazan NG, Mishra YK, Uhal BD, Brufsky A. Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era. ACS Nano 2021;15:8069-86. [PMID: 33826850 DOI: 10.1021/acsnano.1c00629] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 53.0] [Reference Citation Analysis]